A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone

NCT00796432 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: OROS paliperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.